Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology by unknown
Rais et al. BMC Women's Health 2012, 12:35
http://www.biomedcentral.com/1472-6874/12/35RESEARCH ARTICLE Open AccessTriple negative breast cancer in Moroccan
women: clinicopathological and therapeutic study
at the National Institute of Oncology
Ghizlane Rais1*, Soundouss Raissouni1, Meryem Aitelhaj1, Fadoi Rais2, Sara Naciri1, Siham Khoyaali1,
Halima Abahssain1, Youssef Bensouda1, Basma Khannoussi3, Hind Mrabti1 and Hassan Errihani1Abstract
Background: Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. This is an aggressive malignancy
with a poor prognosis despite the high rates of response to chemotherapy. The aim of this study is to determine
the clinicopathological, therapeutic features and outcomes associated with this type of breast cancer.
Methods: This is a retrospective study of confirmed triple negative breast cancer females collected at the
National institute of oncology of Rabat in Morocco, between January 2007 and December 2008. Epidemiological,
clinical, histological, therapeutic and evolutive data were analyzed. OS and DFS rates were estimated by
Kaplan-Meier analysis.
Results: A total of one 152 patients with breast cancer, were identified as having triple-negative breast cancer
(16,5%). The median age at diagnosis was 46 years. 130 patients (86%) had infiltrating ductal carcinoma and
thirteen had medullar carcinoma (9%). 84 cases (55%) were grade III Scarff-Bloom-Richardson (SBR). 48 % had
positive lymph nodes, and 5 % had distant metastases at diagnosis. According TNM staging, 12 patients (8%) had
stage I, 90 patients (60%) had stage II and the 43(28%) had stage III. 145 patients received surgery. 41 (28%) had
conservative surgery and 104 (72%) received radical mastectomy with axillary lymph nodes dissection. 14 patients
with advanced tumors or inflammatory breast cancer have received neoadjuvant chemotherapy and four patients
(28%) had complete pathologic response. From 131 patients how received adjuvant chemotherapy, 99 patients
(75,5%) had Anthracycline based chemotherapy) and 27 patients (20,6%) had sequential Anthracycline and
docetaxel,. Seven patients with metastatic disease received anthracycline-based regimen in the first line metastatic
chemotherapy. The median follow-up time was 46 months (range 6,1 -60 months). Overall survival at 5 years for all
patients was 76,5%.
Conclusion: These results suggest that most TNBC characteristics in Moroccan patients are in accordance with
literature data, especially concerning young age at diagnosis high grade tumors, advanced stage at diagnosis, and
short time to relapse. Although the high response rate to chemotherapy, the overall prognosis of this subset of
tumors remains poor.* Correspondence: medghiz@hotmail.com
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Breast cancer affected an estimated 232,620 women and
men in 2011, and was responsible for 39,970 deaths dur-
ing the same year, in the United States [1]. It is now
widely recognized that is a heterogeneous disease com-
posed of different subtypes, characterized by their differ-
ent clinic-pathological features, prognoses and responses
to treatment [2,3]. Recently, five distinct gene expression
profile-based “intrinsic” subtypes were identified by c
DNA microarray analysis. Luminal A (ER+and/or pro-
gesterone receptor positive [PR+], HER2−,low Ki67), lu-
minal B (ER+ and/or PR+, HER2+ (or HER2- with high
Ki67)), basal-like (ER−, PR−, HER2−, cytokeratin 5/6
positive, and/or HER1+), HER2+/ER− (ER−, PR−, an
HER2+), and unclassified (negative for all 5 markers) [2-
4]. [4]. Triple-negative breast cancer (TNBC) is defined
by the lack of estrogen receptor (ER), progesterone re-
ceptor (PR), and human epidermal growth factor recep-
tor 2 (HER-2) expression [4]. It is important to clarify
that the terms “triple negative” and “basal-like” are not
completely synonymous, illustrating an approximately
20%–30% discordance across several studies [5]. The
term triple negative refers to the immunohistochemical
classification, whereas the basal-like subtype is defined
via gene expression microarray analysis. In TNBC ,we
can distinguish between two groups: basal-like (ER-, PR-,
Her2-, cytokeratin (CK) 5/6+ and/or Her1+) and unclas-
sified subtype (ER-, PR-, Her2-, Her1- and CK5/6-). The
incomplete overlap between basal and TN breast cancers
could translate true differences in their biology. Triple-
negative tumors represent a more heterogeneous group
than basal tumors, and include basal and non-basal
tumors very different both at the histoclinical and mo-
lecular level [5].
Approximately 15-20% of breast cancers are triple
negative [6,7], the majority of them are from the basal-
like subtype. TNBC occurs disproportionately in
younger women (<50 years) [6-10], in African-American
women [11,12], and in carriers of BRCA1 [6]. To date,
studies on Moroccan patients with TNBC have been
limited by small sample sizes and short follow-up times
[13]. To some extent, this is because the TNBC is based
on immunohistochemical staining of tumor slides, to
identify the overexpression of HER 2 neu (HER2) and
these were not in general clinical use before 2007. The
specific aim of this review was to characterize this popu-
lation in clinical terms. However, we tried to determine
retrospectively the incidence and survival of TNBC
patients in the National Institute of Oncology in
Morocco.
Methods
The National Institute of Oncology database was used to
identify patients with triple negative breast cancerbetween January 2007 and December 2008. We excluded
from the study patients who had not follow up after ini-
tial diagnosis. The scientific comity of National Institute
of Oncology approved the retrospective review of the
medical records for the purposes of the current study.
Breast carcinoma diagnosis was made by biopsy of the
breast tumor. Patient information was recorded at ac-
crual and included details about the patient’s age at diag-
nosis (in years), tumor grade, lymph node status,
pathologic tumor size in centimeters, and treatment
(surgery, chemotherapy, and radiation treatment).
Tumor staging was carried out according to the TNM
classification 2002 modified in 2003. Histological tumor
grading was performed using the Scarff Bloom and
Richardson (SBR) histological system. Immunohisto-
chemistry: Immunohistochemical analysis to determine
estrogen (ER) and progesterone receptor (PR) status was
performed using standard procedures on 4-μm sections
of paraffin embedded tissue specimens stained with the
monoclonal antibodies 6F11 and 1A6 for ER and PR, re-
spectively. Nuclear staining 10% was considered a posi-
tive result. The Hercept test was realized in the institute
since 2007, subsequently, HER2 status was not routinely
determined for all patient treatment during the course
of this study. Assays are scored with a 4-tiered system
(0–3+). HER2 positivity was defined as strong complete
membrane staining in at least 10% of tumor cells.
Patients were considered HER2-positive if they had
immunohistochemistry (IHC) 3+ by DAKO herceptest.
Tumors exhibiting equivocal HER-2 expression, denoted
as 2+ membranous staining of tumor cells, are con-
firmed by fluorescence in situ hybridization (FISH) at
an outside laboratory. A signal ratios (HER2: CEP17) of
≥ 2.2 were classified as amplified. In the absence of posi-
tive FISH data, tumors scored 2+ by IHC were consid-
ered negative for HER-2. Nine hundred eighteen
patients of 2004 patients (45,8%) had sufficient details
on hormone receptors and HER2 for classification.
Treatment
Patients with local disease had received corresponding
local treatments (surgery plus radiotherapy) and sys-
temic treatments (mainly adjuvant and/or neoadjuvant
chemotherapy). The main surgical operations included
radical mastectomy (Patey type mastectomy) and breast
conserving surgery when permitted by tumor size
according to the judgment of the multidisciplinary care
team. Patients how had metastatic disease at diagnosis
received mono or poly chemotherapy based on the char-
acteristics of the tumors and the aggressiveness of the
disease. These patients have received palliative radiother-
apy if indicated.
In our institute and in the study period, adjuvant
chemotherapy in TNBC patients was indicated in the
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nodal status, grade 2 or 3 SBR, and age ≤ 35 years. Neo-
adjuvant chemotherapy was giving in patients with in-
flammatory or locally advanced breast cancer. For the
patients who did not receive adjuvant chemotherapy,
they have received neo adjuvant chemotherapy or they
did not return after surgery for personal reasons.
For patients receiving neoadjuvant chemotherapy,
Chevalier classification was used to classify histological
response to neo-adjuvant chemotherapy in the breast
[14]. A pathologic complete response (pCR) was defined
as no evidence of invasive carcinoma in the breast and
the axillary lymph nodes at the time of surgery (grade 1
and 2 of Chevalier classification).
Anthracycline containing regimens were mainly used
for adjuvant and/or neo-adjuvant chemotherapy (AC60
protocol with Doxorubicin 60 mg/m2, Cyclophosphamide
600 mg/m2 and FEC 100 protocol with Fluorouracil 500
mg/m2, Epirubicin 100 mg/m2 IV, Cyclophosphamide
500 mg/m2). Docetaxel was administered at a dose of
100mg/m2 when used in monotherapy and at a dose of 75
mg/m2 in combination with Anthracycline. The choice of
chemotherapy protocols depended on the availability of
products at the time of the indication.
Adjuvant radiotherapy was indicated in the case of
tumor size greater than 5 cm, invasion of the pectoral
fascia, more than four metastatic axillary lymph nodes,
positive surgical margin and breast conservation.
Follow up
Patients were followed up until December, 2011. All
patients who are not reviewed in the last consultation
were contacted again by telephone. Locoregional recur-
rence mean the recurrence in ipsilateral mammary
glands, chest wall, or regional lymph nodes identified
clinically or histologically, while distant metastasis re-
ferred to the metastatic carcinoma detected by clinical
examination or imaging. OS (Overall survival) was cal-
culated from the date of diagnosis (fin needles aspir-
ation, biopsies or radical mastectomy) to the date of
death or last follow-up. DFS (Disease free survival) was
measured from the date of surgery or the first course of
neoadjuvant chemotherapy to the date of last follow-up
or disease relapse. Patients with stage IV disease at diag-
nosis were excluded from the statistical evaluation of
DFS.. OS were calculated for all patients of the study.
DFS and OS were also evaluated according to the stage
for patient with localized disease.
Statistical analysis
SPSS 18.0 software was used for statistical analysis. De-
scriptive of clinical data were expressed in percentage or
median or mean ± SD. OS and DFS rates were estimated
by Kaplan-Meier analysis.Consent and statement of ethical approval
As the treatment of each patient was decided by the
medical staff of the centre, oral consent was obtained
from the subjects and was approved by the institutional
review boards of the National Institute of Oncology,
Cancer Centre in Rabat. This study was approved by the




The Her2 status gene amplification was performed in
Nine hundred eighty breast cancer patients treated in
the national institute of oncology between January 2007
and December 2008. A total of one hundred and fifty
two patients with breast cancer, were identified as having
triple-negative breast cancer (16,5%). The median age at
diagnosis (±standard deviation) was 46 years (range 25-
79years). Twelve patients (7,8 %) had a family history of
breast cancer. The identification BRCA mutation was
not performed in any patient. One hundred and thirty
three patients (87,5%) had nursing antecedents and
thirty five patients (23%) reported the use of oral contra-
ceptives. One hundred and thirty patients (86%) had in-
filtrating ductal carcinoma, thirteen had medullar
carcinoma (9%), 4 had infiltrating lobular carcinoma, 3
had mixed ductal and lobular carcinomas and the two
remaining patients had metaplasic carcinoma . Eighty
four cases (55%) were grade III Scarff-Bloom-Richardson
(SBR), 62 patients( 41%) were grade II and only six (4%)
were grade I. Vascular invasion was found in 65 patients
(43%). For the lymph node involvement: 48 % had posi-
tive lymph nodes, and 5 % had distant metastases.
According TNM staging, 12 patients (8%) had stage I, 90
patients (60%) had stage II , 43(28%) had stage III and 7
(4%) patients had stage IV at first diagnosis. among these
last patients group, three had bone metastases only, 3
had bone, lung, brain and liver metastases and one pa-
tient has diffuse cutaneous metastases. The median
follow-up time was 46 months (range 6,1 -60 months).
Overall survival at 5 years for all patients was 76,5%
(Figure 1). Table 1 summarizes patients characteristics.
Treatment details and outcomes
Non metastatic disease
One hundred and forty five patients received surgery.
Forty one patients (28%) had conservative surgery
(tumorectomy with axillary lymph nodes). The
remaining patients (72%) received radical mastectomy
with axillary lymph nodes dissection (Patey type mastec-
tomy) (Table 2). All patients with local disease, who were
operated, received optimal surgery with free histological
margins. Fourteen patients with advanced tumors or in-












Time from diagnosis (months)
Figure 1 Overall survival at 5 years for all patients.
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(85,7%) had Anthracycline based chemotherapy
(AC60and FEC100) and two patients received Anthra-
cycline and taxane based protocol (3 cycles of AC60
folowed by 3 cycles of docetaxel). Four patients (28%)
had complete response to neoadjuvant chemotherapy.
Ten patients had a chevalier response 3 and 4 (37 and
63% respectively) (Table 2). From 131 patients how
received adjuvant chemotherapy, 99 patients (75,5%)
had Anthracycline based chemotherapy(AC60, FAC 50
and FEC100), 27 patients (20,6%) had sequential
Anthracycline and docetaxel, and 4 patients (3%)
received docetaxel as adjuvant chemotherapy. Seven
patients received previous neoadjuvant chemotherapy
(Table 2).
At last follow up, four patients (2,7 %) experienced
local relapse, twenty seven patients (18,49%) had meta-
static progression and 26 patients (17,8%) died. For all
patients with localised disease, OS and DFS at 5 years
were 79,7 and 77,8% respectively (Figure 2a,b) (Figure 3).
OS were 92,3, 86,5 and 57,8 for stage I, II and III
respectively.Metastatic disease
Seven patients with metastatic disease received
anthracycline-based regimen in the first line metastatic
chemotherapy: four patients received AC 60 protocol,
one patient received FEC100 protocol and two patients
received AT protocol (Table 2). Three patients received
second line chemotherapy. At the end of the study, all
these patients have died.Discussion
This study conducted at the national institute of oncol-
ogy in morocco analyzed the epidemiological, clinical,
and therapeutic characteristics of TNBC. Only one re-
cent report has evaluated the demographics and clinical
presentations of this subtype in Moroccan population
[13]. The current study represents a large retrospective
review of 152 patients with a diagnosis of TNBC in our
institution over 2-year period (2007–2008) and is to our
knowledge the largest series in our context focusing on
this particular population. Most of demographic and
clinical features of our study group are in accordance
with previous findings in the literature.
Of nine hundred eighty breast cancer patients, diag-
nosed between 2007 and 2008, with available immunos-
taining data, 16,5% were assessed as TNBC. In the
US, approximately 15-20% of breast cancers are TNBC
[6,7]. However, some studies have suggested that its
prevalence differs between races with a higher preva-
lence reported among African-American women and
Hispanic [8,9].
TNBC are associated with a younger age at presenta-
tion, having a mean age of 53 years old, compared to 58
years old for other subgroups in a study reported by
Dent and al [7]. However, until now, there is still no final
conclusion about whether age is a risk factor of TNBC,
and there are still inconsistent findings in previous clin-
ical studies. In our study population, the median age at
diagnosis (46 years) was younger than the average age
mostly reported in the United States [6,7] but may be
comparable to the median age in Hispanic triple nega-
tive breast cancer patients [8,9]. Additionally, thirty two
Table 1 Clinical characteristics and outcomes of all
patients
Characteristics No. of patients (%)
Median age at diagnosis 46 years
Median histological tumor diameter 4cm
Triple negative breast cancer 16,5%
Nursing 121 59








Invasive ductal carcinomas 130 86
Medullar carcinoma 13 9
Others types 9 5
Vascular invasion 65 43





Stage I 12 8
Stage II 90 59
Stage III 43 28
Stage IV 7 5
Overall survival at 5 years
Table 2 Treatment modalities and Outcomes of non
metastatic patients
N. of patients (%)
Surgery 145
Radical mastectomy 104 72
Conservative surgery 41 28
Chemotherapy
Neoadjuvant chemotherapy 14 10
pCR 4 28
Adjuvant chemotherapy 131 90
Anthracycline based regimens 99 75
Sequentiel anthracycline taxane 27 20
Taxane alone 4 5
Outcomes




Disease free survival at 5 years 77,8
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that there might be factors that may predispose them to
development of this disease. Given that the early age at
onset is generally considered an indicator of genetic sus-
ceptibility to breast cancer and the fact that triple nega-
tive entity most often presents at a young age, an
important part of future progress will be the identifica-
tion of subgroups who may have a higher personal or fa-
milial risk of developing TNBC.
From an epidemiologic perspective, the known risk
factors for triple-negative disease are modest, suggesting
few clear interventions. Race appears to be a risk factor,
as TNBC is more frequent in premenopausal patients of
African-American heritage [6,10]. There is also some
suggestion that TNBC are more prevalent among
women who reside at a lower socioeconomic level
and/or lack access to healthcare [11,12]. In the current
study, no racial or socioeconomic specificity have
been identified.What is less well known is whether anthropometrics,
demographics, and reproductive history are independ-
ently associated with TNBC. Previous population-based
work has observed that younger age at menarche or
younger age at first pregnancy, higher parity, shorter
duration of breast feeding, higher body mass index
(BMI) or higher waist to-hip ratio (WHR) were all asso-
ciated with basal-like tumors versus luminal A tumors
(tumors characterized by positive ER and PR and nega-
tive HER2) [15]. Oral contraceptive use for more than
one year was associated with a 2.5-fold increase in the
incidence of TNBC [16,17]. It has been proposed that
the mechanism through which oral contraceptives use
impacts the risk of breast cancer among young women
is that estrogen promotes the growth of breast cancer-
enhancing angiogenesis and stromal cell recruitment
[18]. In the current series, oral contraception was found
in 23% of our patients.
This study found less than 10% of family history of
breast cancer. Unfortunately, the research of a BRCA1/2
gene mutation was not performed due to its non avail-
ability in the time of study period.
Recently, the association between BRCA1 mutations
and the development of TNBC is well established [19].
In a recent report, Gonzalez – Angulo and al found a
19.5% incidence of BRCA mutations [20]. Review of the
spectrum of breast cancer tumor subtypes, which in-
clude basal-like, triple-negative and BRCA1-positive
tumors, suggest that they have overlapping clinical,
pathologic and molecular features, which are different





























Figure 2 (a) overall survival at 5 years for non metastatic patients, (b) disease free survival at 5 years for non metastatic patients.
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to a better understanding of the molecular pathology of
these aggressive tumors and the identification of possible
therapeutic targets [21]. More recently, poly (ADP-
ribose) polymerase PARP inhibitors appear to take
advantage of the concept of synergic lethality, or dual
pathway inhibition, in attacking triple-negative and BRCA-












Figure 3 Survival for localized patients accordigng to TNM staging.than 10% of family history of breast cancer. Unfortu-
nately, the research of a BRCA1/2 gene mutation was
not performed due to its non availability in the time of
study period.
Reviews data from others cases series show that a
lower proportion of triple-negative breast cancers are
discovered by mammography, which is possibly related
to the age distribution of these patients [6,10]. In our(months)
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to be detected through clinical exam than through im-
aging, such as mammography and ultrasound. This may
reflect a more rapid growth rate and the probable neces-
sity of mammography screening in younger patient < 50
in our country.
Clinically, TNBC Patients had relatively large tumors
(two thirds were >2 cm) and a high rate of node positiv-
ity (48%). Other reports have observed that patients with
TNBC generally present at a similar stage compared to
other tumors [7,8,16], but appear to have an inferior out-
come [7,8,16,19]. This inferior prognosis has been found
to be independent of several other factors such as tumor
grade, size and nodal status [24].
Histologically, TNBC are associated with a higher
histological grade, marked cellular pleomorphism, in-
crease mitotic activity and atypical mitotic figures
[25,26]. Similarly, in our series, TNBCs are characterized
by a frequent ductal histology, high grade in two third of
patient, and high proliferation and mitotic rates.
Triple negative breast cancer in the studied patients
was more frequently diagnosed at advanced stage. Con-
sequently, the majority of patients received radical mast-
ectomy. Only 23% of our patients with local disease
received conservative surgery. Haftty et all demonstrates
in a previous report that there was no evidence that
TNBC patients are at higher risk for local relapse after
conservative surgery and radiation although triple nega-
tive have a poor prognosis [27].
Dent and al reports that the pattern of distant recur-
rence was strikingly different between cancer subgroups.
In patients with triple negative breast cancer, the risk of
any recurrence rose sharply from date of diagnosis,
peaked 1 to 3 years, and dropped quickly thereafter.
The patients outcomes (OS and DFS) in our series are in
accordance with other previous reports [7,27].
TNBC clearly represents an important clinical chal-
lenge. This is due to poor disease-free intervals in the
adjuvant and neoadjuvant setting, shortened
progression-free survival associated to a more aggressive
clinical course in the metastatic setting, and the lack of
targeted therapy [7]. Most recent studies in triple-
negative disease are directed to better identify effective
treatment options and improve outcomes in these
patients. Chemotherapy is known to be effective in
triple-negative disease, and advances in chemotherapy
have particularly benefited this patient group. However,
there is not a clear, proven effective single agent
that targets a driving vulnerability in triple-negative
breast cancer.
Although response to chemotherapy is high in the
neoadjuvant setting, the overall prognosis of this subset
of tumors remains poor. Liedtke and al demonstrates in
a previous report that patients with TNBC haveincreased pathologic complete response (pCR) rates
compared with non-TNBC, and also had better survival
compared to TNBC patients who don’t achieve pCR.
Conclusion
However, a poorer prognosis was seen in the triple-
negative subgroup with residual disease (RD) after com-
pleting neoadjuvant chemotherapy, particularly in the
first 3 years [28]. The systemic effect of neoadjuvant
chemotherapy on the immune system deserves to be ac-
curately investigated. Several researchers have dedicated
their attention to cancer immune response in order to
identify prognostic factors and immunological targets
[29]. In a recent study, Denkert and al reported that it is
possible to identify a subgroup of breast carcinomas that
is characterized by a lymphocytic infiltrate In the tumor
tissue and a particularly strong response to chemother-
apy [30,31].In our series, 28% of patients receiving
neoadjuvant chemotherapy achieved pCR, which is in
accordance with the literature [5,28].
Most approaches in triple-negative disease consist of
more targeted chemotherapy, growth factor pathway
approaches, and BRCA1-driven approaches. Many anti-
angiogenic treatments have been introduced or are cur-
rently under development, and may hold promise for
patients with triple-negative breast cancer. Bevacizumab
has the most data in breast cancer [30]. In a recent re-
port from Von Minckwitz and al, the addition of bevaci-
zumab to neoadjuvant chemotherapy significantly
increased the rate of pathological complete response
among patients with HER2-negative early-stage breast
cancer. Efficacy was restricted primarily to patients with
triple-negative tumors, in whom the pathological
complete response is considered to be a reliable pre-
dictor of long-term outcome [32,33].
In metastatic setting, three randomised clinical trials
(E2100, AVADO and RIBBON I) has proven the efficacy
of Bevacizumab combined with chemotherapy, especially
with taxanes, as the first line treatment of metastatic
breast cancer. The combination improved patient
progression-free survival in all trials with no impact on
the known toxic effects of taxanes. This may be a potent
treatment option particularly for patients with triple
negative breast cancer [32,34].
As mentioned previously, PARP inhibition may be an-
other therapeutically valuable mechanism in patients
with triple negative disease. Some clinical data are avail-
able to support this approach. In one phase II study of
olaparib, an oral PARP inhibitor was conducted in pre-
treated BRCA1 or BRCA2 mutation carriers, 41% exhib-
ited response to this therapy [35]. Another PARP
inhibitor, Iniparib, is an i.v. agent studied first in a ran-
domized phase II of patients with metastatic triple-
negative disease. Patients were randomized to receive
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addition of Iniparib. This trial, suggested that the
addition of iniparib to chemotherapy improved the clin-
ical benefit and survival of patients with metastatic
triple-negative breast cancer without significantly
increased toxic effects. However, this result was not con-
firmed by the phase III trial presented at the 2011 ASCO
Annual Meeting. [35,36]. The selection of patients who
may benefit from these agents is essential, for instance,
these agents may prove to be effective only in patients
with BRCA1 or BRCA2 mutations
The majority of triple-negative breast cancer tumors
overexpress the EGFR(epidermal growth factor recep-
tor). EGFR has been considered as a sensible target in
basal-like and triple negative breast cancer. Cetuximab,
which is an anti-EGFR monoclonal antibody, was added
to carboplatin therapy in a pretreated triple-negative co-
hort, with a modest response rate of 17% [37]. Mean-
while, in a subset of the U.S. Oncology 225200 trial, the
addition of cetuximab to carboplatin and irinotecan led
to a higher response rate, 49% versus 30%, but did not
improve the PFS interval. However, cetuximab blocked
expression of the EGFR pathway in only a minority, sug-
gesting that most had alternate mechanisms for pathway
activation [38,39].
In summary, this report documents the clinical experi-
ence of TNBC at our institution. This study is limited by
our unfortunate inability to determine the exact inci-
dence of TNBC and to do the comparative study with
other breast cancer subtype. In addition, the lack of
cytogenetic investigation of BRCA gene mutation due to
the low socioeconomic level of these patients and the
lake of Her-2 gene amplification test in the half of breast
cancer patients diagnosed in our institution are two
major limitations.
However, our results suggest that most TNBC charac-
teristics in Moroccan patients are in accordance with lit-
erature data, especially concerning young age at
diagnosis high grade tumors, advanced stage at diagno-
sis, and short time to relapse. Because mammography
screening programs should improve early detection
rates for breast cancer, and because the early detection
of TNBC is critical for improving likelihood of its
successful treatment, we believe that screening
mammography is particularly important for young Mo-
roccan women.
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